The Securities Exchange Board of India (Sebi) has confirmed reports that it had received a whistleblower complaint against Sun Pharma.
A whistleblower sent Sebi a 150-page letter last month alleging various irregularities by Sun Pharma. It is being reported that the allegations have to do with insider trading and other issues involving fundraising overseas.
Sun Pharma published a point by point press release addressing these media reports, opening with, "there have been some media reports on Sun Pharma around a note issued by one of the securities firm and a potential whistleblower complaint against the company." According to points addressed in this press release, Sun has not received any query related to this from SEBI.
Read the ET coverage